Sphingosine 1-Phosphate (S1P) Lyase Deficiency Increases Sphingolipid Formation via Recycling at the Expense of de Novo Biosynthesis in Neurons*

Background: Knock-out of S1P lyase, the only enzyme cleaving the sphingoid backbone, causes a severe phenotype. Results: S1P lyase deficiency affects sphingolipid and cholesterol metabolism and also expression of Orm1/3 proteins. Conclusion: Accumulation of free and phosphorylated sphingoid bases by loss of S1P lyase causes readjustment of the balance between de novo biosynthesis and recycling to maintain (glyco)sphingolipid homeostasis. Significance: Data provide the first evidence for a mechanism that enables maintenance of (glyco)sphingolipid homeostasis in the brain. Sphingosine 1-phosphate lyase (S1P lyase) irreversibly cleaves sphingosine 1-phosphate (S1P) in the final step of sphingolipid catabolism. As sphingoid bases and their 1-phosphate are not only metabolic intermediates but also highly bioactive lipids that modulate a wide range of physiological processes, it would be predicted that their elevation might induce adjustments in other facets of sphingolipid metabolism and/or alter cell behavior. Indeed, we have previously reported that S1P lyase deficiency causes neurodegeneration and other adverse symptoms. We next asked the question whether and how S1P lyase deficiency affects the metabolism of (glyco)sphingolipids and cholesterol, two lipid classes that might be involved in the neurodegenerative processes observed in S1P lyase-deficient mice. As predicted, there was a considerable increase in free and phosphorylated sphingoid bases upon elimination of S1P lyase, but to our surprise, rather than increasing, the mass of (glyco)sphingolipids persisted at wild type levels. This was discovered to be due to reduced de novo sphingoid base biosynthesis and a corresponding increase in the recycling of the backbones via the salvage pathway. There was also a considerable increase in cholesterol esters, although free cholesterol persisted at wild type levels, which might be secondary to the shifts in sphingolipid metabolism. All in all, these findings show that accumulation of free and phosphorylated sphingoid bases by loss of S1P lyase causes an interesting readjustment of the balance between de novo biosynthesis and recycling to maintain (glyco)sphingolipid homeostasis. These changes, and their impact on the metabolism of other cellular lipids, should be explored as possible contributors to the neurodegeneration in S1P lyase deficiency.

Sphingosine 1-phosphate lyase (S1P lyase) irreversibly cleaves sphingosine 1-phosphate (S1P) in the final step of sphingolipid catabolism. As sphingoid bases and their 1-phosphate are not only metabolic intermediates but also highly bioactive lipids that modulate a wide range of physiological processes, it would be predicted that their elevation might induce adjustments in other facets of sphingolipid metabolism and/or alter cell behavior. Indeed, we have previously reported that S1P lyase deficiency causes neurodegeneration and other adverse symptoms. We next asked the question whether and how S1P lyase deficiency affects the metabolism of (glyco)sphingolipids and cholesterol, two lipid classes that might be involved in the neurodegenerative processes observed in S1P lyase-deficient mice. As predicted, there was a considerable increase in free and phosphorylated sphingoid bases upon elimination of S1P lyase, but to our surprise, rather than increasing, the mass of (glyco)sphingolipids persisted at wild type levels. This was discovered to be due to reduced de novo sphingoid base biosynthesis and a corresponding increase in the recycling of the backbones via the salvage pathway. There was also a considerable increase in cholesterol esters, although free cholesterol persisted at wild type levels, which might be secondary to the shifts in sphingolipid metabolism. All in all, these findings show that accumulation of free and phosphorylated sphingoid bases by loss of S1P lyase causes an interesting readjustment of the balance between de novo biosynthesis and recycling to maintain (glyco)sphingolipid homeostasis. These changes, and their impact on the metabolism of other cellular lipids, should be explored as possible contributors to the neurodegeneration in S1P lyase deficiency.
In mammals, the brain exhibits the highest lipid content in the body next to adipose tissue. Complex sphingolipids, such as glycosphingolipids (GSLs), 2 especially the sialic acid-containing gangliosides, are particularly abundant in neuronal cells (1). Metabolic intermediates of these lipids, notably sphingosine, ceramide, and S1P, function as bioactive molecules by regulating numerous cellular signaling pathways (2).
Sphingolipid biosynthesis starts with the condensation of serine and palmitoyl-CoA to form 3-ketosphinganine catalyzed by serine palmitoyltransferase (SPT). 3-ketosphingosine is then reduced to dihydrosphingosine. The latter is N-acylated to dihydroceramide by a family of ceramide synthases (CerS), each of which uses a restricted subset of fatty acyl-CoAs (3). The formed dihydroceramide is finally desaturated to ceramide, the membrane anchor of all sphingolipids (1,2). S1P is the common catabolic intermediate of all sphingolipids and is formed via deacylation of ceramide, yielding sphingosine. Sphingosine is then either phosphorylated by sphingosine kinases (SKs) to S1P or reused for ceramide formation. Until now, two isoforms of sphingosine kinase, SK1 and SK2, have been cloned and characterized (4,5). They differ in their kinetic properties and are active at different subcellular sites. S1P phosphatase catalyzes dephosphorylation of S1P back to sphingosine that can be recycled for sphingolipid formation via a recycling or salvage pathway. A decisive step in the catabolism of sphingolipids is carried out by S1P lyase, encoded by the Sgpl1 gene (6). S1P lyase, which resides in the endoplasmic reticulum (ER) and is widely distributed in tissues, catalyzes the final catabolic step of the sphingolipid degradation pathway, cleaving S1P into phosphoethanolamine and hexadecenal (7). Notably, S1P lyase is the only enzyme that enables sphingoid substrate to irreversibly exit the sphingolipid metabolic pathway. The importance of S1P lyase was demonstrated in several publications wherein the phenotype of the S1P lyase-deficient mice was described and analyzed (8 -11). S1P lyase-deficient mice already show retarding growth at day 6 after birth. In addition, life expectancy of these mice is generally reduced to 6 -8 weeks. Their reduced body weight (to about half of their age-matched littermates) is accompanied by the complete absence of adipose tissue (8). However, the amount of lipids including sphingolipids and cholesterol is considerably elevated in serum and liver of these mice (8).
We showed that in neurons derived from S1P lyase-deficient mice, S1P is neurotoxic when generated by SK2 (10). In addition, we found that neurons that abundantly express S1P lyase in wild type mice are those that degenerate first in S1P lyase-deficient mice (12). We now asked the question whether and how S1P lyase deficiency affects the metabolism of sphingolipids and cholesterol, two lipid classes that might be involved in the neurodegenerative processes observed in these mice.
Our findings suggest that disruption of the Sgpl1 gene causes the expected elevation of sphingoid base phosphates and to a much lesser extent of free sphingoid bases but does not significantly alter the content of ceramide, sphingomyelin, and GSLs. However, de novo formation of sphingolipids is substantially decreased, whereas the recycling pathway is significantly increased in these neurons. Furthermore, the amount of free cholesterol in the brains of S1P lyase-deficient mice was unaffected, whereas the content of cholesterol esters doubled.
Data Analysis-All experiments were repeated at least three times with consistent results. Quantitative analysis was done from at least three different thin layer chromatography (TLC) plates. Data are expressed as means Ϯ S.D. and normalized as indicated. Statistical analysis was performed using Student's t test. *, significantly different from wild type (p Ͻ 0.05).

S1P Lyase Deficiency Affects Primarily Mass of Sphingoid
Bases and Their Phosphates in Neurons-Using liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS), we have recently shown that the amount of sphingosine and especially that of S1P considerably increases in neurons lacking S1P lyase activity (10). We have now extended these measurements and observed that the amount of the saturated counterparts sphinganine and sphinganine 1-phosphate are less affected in these neurons (Fig. 1A). The amount of S1P increased from 200 pmol/mg in wild type neurons to about 4500 pmol/mg in S1P lyase-deficient neurons. Sphingosine levels increased about 3-fold (from 1200 pmol/mg in wild type neurons to 3500 pmol/mg in S1P lyase-deficient neurons). Thus, nearly similar amounts of sphingosine and S1P could be detected in S1P lyase-deficient neurons. Sphinganine and sphinganine 1-phosphate are much less abundant, amounting to 40 and 12 pmol/mg, respectively, in wild type neurons, and were elevated by about 2-and 10-fold, respectively, in S1P lyasedeficient neurons (Fig. 1A).
To find out whether the increased amounts of sphingosine in S1P lyase-deficient neurons affect the amount of other sphingolipid species, which are formed thereof via the recycling pathway, we determined the mass of ceramide, sphingomyelin, and glucosylceramide (GlcCer) and their dihydro counterparts in wild type and S1P lyase-deficient neurons, respectively. As shown in Fig. 1B, the unsaturated species of these sphingolipids are about 10 times more abundant in neurons than the respective saturated forms. Still, the mass of the unsaturated species was not affected by the absence of S1P lyase activity, whereas the amounts of dihydroceramide and of dihydrosphingomyelin were decreased to some extent (Fig. 1B). Analysis of individual molecular sphingolipid species that differ in the length of the fatty acid in their ceramide backbone revealed some additional particular differences (Fig. 1, C-G). As depicted in Fig. 1, C-G, cerebellar neurons exhibit several molecular species of ceramide, sphingomyelin, and GlcCer, of which those containing palmitic acid (C16:0) or stearic acid (C18:0) in amide linkage to their sphingosine moiety prevail. In the case of ceramide and GlcCer, molecular species containing stearic acid overbalance those with palmitic acid, whereas the reverse is true in the case of dihydroceramide and dihydrosphingomyelin, where molecular species containing palmitic acid overbalance those with stearic acid. Note that only in the case of dihydrosphingomyelin, a third molecular species, namely that containing a long unsaturated fatty acid C24:1 in its ceramide moiety, is nearly as abundant as that containing stearic acid (Fig. 1F). None of the saturated molecular spe-cies of ceramide, sphingomyelin, and GlcCer are significantly changed in S1P lyase-deficient neurons apart from a single exception (Fig. 1, C, E, and G). Only C20-ceramide is significantly reduced by 50% in neurons lacking S1P lyase activity (Fig. 1C). In contrast, the amounts of all saturated dihydro species of ceramide and sphingomyelin are reduced to some extent in S1P lyase-deficient neurons (Fig. 1, D and  F). A maximal reduction of nearly 90% was observed in the case of C16-dihydroceramide in S1P lyase-deficient neurons. The corresponding C16-dihydrosphingomyelin was also significantly reduced by nearly 30% (Fig. 1F). Note that reproducibility of the amounts of dihydro-GlcCer that were close to the detection limit was problematic and is not shown.
As shown in Fig. 2, similar results were obtained for GlcCer and sphingomyelin when separated by TLC and evaluated densitometrically. In addition, it becomes clear from this figure that there were no significant changes in the total amount of gangliosides in S1P lyase-deficient neurons (Fig. 2).

S1P Lyase Deficiency Results in Reduction of de Novo Formation of GSLs and of Sphingomyelin with Simultaneous Enhancement of Recycling Pathway in Neurons-
The massive reduction of the amount of C16-dihydroceramide and also of C18-dihydroceramide (Fig. 1D), both representing crucial biosynthetic intermediates of more complex sphingolipids with nearly no changes in the total amount of ceramides (including dihydroceramides, see Fig. 1B) in S1P lyase-deficient neurons prompted us to carry out metabolic studies in these cells. First we followed the incorporation of [ 14 C]serine into newly formed cellular sphingolipids. As depicted in Fig. 3, incorporation of [ 14 C]serine into cellular sphingolipids of S1P lyase-deficient neurons was considerably reduced. The content of GlcCer, lactosylceramide (LacCer), sphingomyelin, and ceramide (Cer) was greatly decreased by about 40% (Fig. 3, A and C). As a consequence, the de novo formation of complex GSL was also significantly reduced in S1P lyase-deficient neurons. The amount of GD1a and of GQ1b representing the end products of a-and b-series of gangliosides, respectively, in these cells decreased by more than 50%, whereas that of intermediate gangliosides such as GM3, GD3, and GD1b, was reduced by about 30% (Fig. 2B). Note that some intermediate gangliosides of the biosynthetic pathway including GM2 and GM1 were hardly detectable even in wild type neurons (Fig. 3A).
It has been reported previously that in neuronal cells, the salvage pathway in which sphingosine resulting from the degradation of cellular sphingolipids is recycled via ceramide to all sphingolipids contributes considerably to the mass of cellular sphingolipids (18). To assess this pathway, we evaluated the incorporation of [1-14 C]galactose into cellular GSLs. As illustrated in Fig. 4, the amount of radioactively labeled GSLs was significantly higher in S1P lyase-deficient neurons than in wild type neurons. GlcCer and LacCer, both precursors of complex GSLs, amounted to about ϳ150% in neurons derived from S1P lyase-deficient mice when compared with wild type neurons (Fig. 4B). Accordingly, incorporation of radioactivity in all ganglioside species was 30 -50% higher in S1P lyase-deficient neurons. Note that ganglioside GM2, an intermediate of the a-series gangliosides, which is hardly detectable in wild type neurons, is clearly evident in S1P lyase-deficient neurons (Fig. 4).

Reduction of de Novo Formation of GSLs in S1P Lyase-deficient Neurons Is Accompanied by Reduced SPT Activity and Up-regulation of Orm Protein Expression-
The rate-limiting step of de novo sphingolipid biosynthesis is catalyzed by SPT. As depicted in Fig. 5A, SPT activity was considerably reduced (by about 50%) in S1P lyase-deficient neurons. However, the transcript amounts of both SPT subunits were similar in wild type and lyase-deficient cells (Fig. 5B). Recently, Orm1/2 proteins were reported to negatively regulate sphingolipid synthesis in yeast (19,20). We therefore studied the expression of this evolutionarily conserved family of ER-resident proteins in cerebellar neurons. As shown FIGURE 1. S1P lyase deficiency affects primarily mass of sphingoid bases and their phosphates. Neuronal cultures were prepared from wild type (ϩ/ϩ) and S1P lyase-deficient (Ϫ/Ϫ) mouse cerebella. At day 5 in culture, cells were harvested, and lipids were extracted and evaluated by ESI-tandem mass spectrometry as described under "Experimental Procedures." Data are averages of triplicate determinations. Numbers indicate carbon chain length followed by the number of double bounds in the fatty acid moiety. Sa, sphinganine; Sa1P, sphinganine 1-phosphate; Sph, sphingosine; SM, sphingomyelin; DHGlcCer, dihydroglucosylceramide; DHSM, dihydrosphingomyelin; DHCer, dihydroceramide; Cer, ceramide; DHsphingolipids, dihydrosphingolipids.

S1P Lyase Deficiency Is Associated with Increase of Cholesterol Esters but Persisting Free Cholesterol Levels in Nerve Tissue-
The close interaction of sphingolipids and especially of sphingomyelin with cholesterol in cellular plasma membranes is well documented (21,22). Because our results indicated no changes in the amount of plasma membrane-associated sphingolipid species in neurons lacking S1P lyase activity, we evaluated the amounts of free cholesterol and some of its metabolites as well as of cholesterol esters in brains of S1P lyase-deficient and of wild type mice, respectively. In addition, we determined some plant sterols. As becomes clear from Fig. 6, free cholesterol is by far the most abundant sterol fraction in the brain, amounting to nearly 30 g/mg of tissue. Its immediate metabolic precursor desmosterol occurs in considerably lower amounts (about 7 g/mg), whereas two other precursors, lathosterol and lanosterol, amount to only about 0.5 and 0.1 g/mg, respectively. The amounts of the cholesterol-derived metabolites 24(S,R)hydroxy-cholesterol and cholestanol are even much lower (about 20 ng/mg). In the same range are the determined plant sterols, campesterol and sitosterol, which are most probably derived from the ingested animal food. No significant differences of these sterols were observed in brains from S1P lyasedeficient and wild type mice (Fig. 6). By contrast, the levels of cholesterol esters were increased more than 2-fold in brains of S1P lyase knock-out mice when compared with wild type mice (Fig. 6). Note that in wild type animals, esterified cholesterol constitutes less than 5% of total brain cholesterol.

DISCUSSION
In a recent study, we showed that S1P lyase deficiency causes neurodegeneration, which was induced by the accu-mulation of its substrate S1P in the ER (12). We now show that S1P lyase deficiency does not affect the total amount of more complex sphingolipids in neurons despite a significant accumulation of sphingoid bases and their phosphates. By contrast, S1P lyase deficiency causes a considerable elevation of the mass of ceramide and sphingomyelin in liver (8). Note that in liver, a 472-fold increase of S1P and a 42-fold elevation of sphingosine have been reported (8). These amounts are remarkably higher than those obtained in cerebellar neurons in which S1P increased 20-fold and sphingosine increased 3-fold relative to wild type. Thus, the inability to cleave the sphingoid structure has different consequences in different tissues. In neurons, free sphingosine and phosphorylated sphingosine amount to almost equal concentrations with no changes in complex (glyco)sphingolipids, whereas in liver, the content of sphingosine exceeds by far that of S1P and the mass of sphingolipids is considerably elevated (8). Obviously, nervous tissue has a better ability to overcome perturbations of sphingolipid metabolism.
Cell type-and tissue-specific differences in sphingolipid metabolism have been well known for many years. Don Marcus and co-workers (18) suggested in the nineties that in slowly dividing cells in which the need for synthesis is relatively low, GSLs are synthesized predominantly from sphingoid bases recycled from the hydrolytic pathway. Accordingly, in more rapidly dividing cells, the need for increased synthesis is met by up-regulating the de novo pathway (18). Hence, in terminally differentiated, postmitotic neurons, recycling of sphingosine for sphingolipid formation is a well developed common mechanism. The inability to degrade S1P clearly promotes this pathway in neurons. As described earlier, this salvage pathway utilizes S1P as a starting point (23). S1P is dephosphorylated by S1P phosphatase, which resides in the ER to produce sphingosine. Ceramide is then FIGURE 2. Ganglioside profile is not changed in absence of S1P lyase. Cultured wild type (ϩ/ϩ) and S1P lyase-deficient (Ϫ/Ϫ) neurons were harvested, and lipids were extracted. A, isolated lipids were separated by TLC in chloroform/methanol/0.22% CaCl 2 (60: 35:8) and (B) quantified as described under "Experimental Procedures." SM, sphingomyelin. The terminology used for gangliosides is that of Svennerholm (42). Data are averages of triplicate determination and given relative to wild type controls.

S1P Lyase and Neuronal Lipid Metabolism
synthesized via acylation of sphingosine by ceramide synthases from which CerS1 prevails in nervous tissue (24). Ceramide synthases probably trap free sphingosine released from lysosomes at the surface of the ER or in ER-associated membranes. In cell culture models, exogenous sphingosine is taken up by the cells and is largely utilized for the biosynthesis of complex sphingolipids (25)(26)(27)(28). Note that sphingolipids have a turnover of several hours in neuronal cells (29).
Our results document that in S1P lyase-deficient neurons, increased recycling of sphingoid bases is accompanied by a considerable reduction of de novo sphingolipid biosynthesis. This was not surprising as we have observed earlier that accumulation of the semisynthetic S1P analog cis-4-methysphingosine-phosphate is accompanied by down-regulation of de novo sphingolipid biosynthesis (13). In addition, we showed that sphingoid bases modulate de novo sphingo-lipid biosynthesis by down-regulating SPT activity in neurons (30,31). The mechanism underlying this feedback regulation is, however, not known. Nevertheless, in yeast, Orm1/2 proteins were identified as negative regulators of SPT, the enzyme catalyzing the committed step of de novo sphingolipid synthesis located in the ER (19,20). The expression of these proteins is dependent on sphingoid base levels (19,20). Orm1/2/3 are members of a family of evolutionarily conserved ER-resident proteins that were initially associated with ER stress (32). Likewise, high expression levels of Orm1/3 in S1P lyase-deficient neurons might be aimed to reduce the elevated amounts of free and phosphorylated sphingoid bases. This is of vital importance because high amounts of S1P in the ER were shown to cause neuronal death (12). Thus, although the high levels of free and phosphorylated sphingoid bases in S1P lyase-deficient neurons reduce the de novo sphingolipid formation, this appears to be compensated for by increased utilization of the recycling pathway (Fig. 7).
The recycling of long chain sphingoid bases, leading to the regeneration of sphingolipids, has been estimated to contribute from 50 to 90% of sphingolipid biosynthesis depending on the cell type and the stage of differentiation (18,33,34). These metabolic events suggest a critical role for sphingolipid breakdown in sphingolipid biosynthesis and turnover as well as in cellular signal transduction. Interestingly, the majority of endogenous sphingosine is recycled (35). Nevertheless, phosphorylation of 1-3% sphingosine may be sufficient to double the levels of S1P (2). Enlarged levels of intracellular S1P constitute an increase of a bioactive molecule and therefore represent a possible risk for the cell. Activation of the recycling pathway is an opportunity to reduce the intracellular amount of S1P. Our results demonstrate that despite a considerable increase of the recycling pathway, accumulation of intracellular S1P still occurred, suggesting that the capacity of this pathway is not sufficient to counterbalance the accumulating amount of S1P. As reported recently, this elevated amount of S1P is apparently harmful by inducing neuronal apoptosis via a calcium-triggered calpain-mediated mechanism (12).
Although the changes in total sphingolipid amounts were rather small, the shift in sphingolipid metabolism might affect the metabolism of other lipids. Indeed, elevation of cholesterol esters was found. Although cholesterol esters represent only a minor percentage of total cholesterol in the brain, this result might be of pathophysiological relevance. About a decade ago, a direct correlation between cholesterol ester levels and the production of amyloid ␤-peptide, which characteristically accumulates in all forms of Alzheimer disease, was reported (36). Note that investigation of amyloid body formation implies the generation of a conditional S1P lyase knock-out mouse model given the very limited life span of the S1P lyase-deficient mice. We have, however, shown recently (12) that sphingoid base phosphate-dependent neurotoxicity shows similarity with that of the amyloid ␤-peptide in Alzheimer disease (37,38). Both S1P (12) and amyloid ␤-peptide (38) induce an aberrant reactivation of cell cycle events and activation of CDK5 (cyclin-dependent kinase). In . De novo sphingolipid synthesis is reduced in S1P lyase-deficient neurons. Cultured wild type (ϩ/ϩ) and S1P lyase-deficient (Ϫ/Ϫ) neurons were labeled with [ 14 C]serine (2 Ci/ml) for 24 h. Then, cells were harvested, and lipids were extracted, isolated, separated by TLC in (A) chloroform/methanol/0.22% CaCl 2 (60: 35:8) or (B) chloroform/methanol/acetic acid (190:9:1), and (C) quantified as described under "Experimental Procedures." x, unknown compound; SM, sphingomyelin; Cer, ceramide; SL, sphingolipids. Data are averages of triplicate determination and given relative to wild type controls. MARCH 16, 2012 • VOLUME 287 • NUMBER 12 addition, S1P (12) and amyloid ␤-peptide (37, 39) neurotoxicity involves calpain and procaspase-12 activation by disruption of ER calcium homeostasis but not by membrane-or mitochondria-targeted signals. In addition, it has been shown recently that cell-associated S1P stimulates the activity of BACE1, the rate-limiting enzyme for amyloid ␤-peptide production (40).

S1P Lyase and Neuronal Lipid Metabolism
Free cholesterol, which constitutes about 95% of total brain cholesterol, persisted at wild type levels in the brains of S1P lyase-deficient mice, although elevated levels of cholesterol were found in serum and liver of these animals (8). This is, however, not surprising because stability of cholesterol homeostasis in the brain has already been demonstrated experimentally. Total brain cholesterol content and thus cholesterol homeostasis were maintained in guinea pigs despite administration of high doses of statins or high dietary cholesterol intake (41).
Our results show that the impact of S1P lyase deficiency on sphingolipid and cholesterol metabolism is less dramatic in neurons than in liver. (Glyco)sphingolipid homeostasis is maintained in neurons even in the absence of S1P lyase activity due to an interesting readjustment of the balance between de novo FIGURE 4. Sphingolipid recycling pathway is elevated in S1P lyase-deficient neurons. Cultured wild type (ϩ/ϩ) and S1P lyase-deficient (Ϫ/Ϫ) neurons were labeled with [ 14 C]galactose (2 Ci/ml) for 24 h. Then, cells were harvested, and lipids were extracted, isolated (A), separated by TLC in chloroform/ methanol/0.22% CaCl 2 (60: 35:8), and (B) quantified as described under "Experimental Procedures." Data are averages of triplicate determination and given relative to wild type controls. FIGURE 5. S1P lyase deficiency is accompanied by decreased SPT activity and up-regulation of Orm protein expression. Cultured wild type (ϩ/ϩ) and S1P lyase-deficient (Ϫ/Ϫ) neurons were harvested. A, SPT activity was assayed in cell homogenate as described under "Experimental Procedures." B-D, alternatively, mRNA content of SPT subunits (B) and Orm proteins (C and D) was quantified by RT-PCR using 18 S mRNA as reference.
biosynthesis and recycling. Nonetheless, the changes in S1P and cholesterol esters should be explored further as possible contributors to the neurodegeneration reported in S1P lyasedeficient mice.